MAG
VRTX icon

Meadowbrook Advisors Group’s Vertex Pharmaceuticals VRTX Stock Holding History

Meadowbrook Advisors Group’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$343K Sell
691
-427
-38% -$189K 0.18% 116
2026
Q1 		$499K Sell
1,118
-33
-3% -$15.4K 0.3% 78
2025
Q4 		$522K Buy
+1,151
New +$496K 0.29% 78

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Meadowbrook Advisors Group's VRTX Position: Q2 2026 in Review

Meadowbrook Advisors Group reduced its Vertex Pharmaceuticals (VRTX) stake by 38% in Q2 2026, selling an estimated $189K and leaving 691 shares worth $343K. The position accounts for 0.18% of the portfolio, ranked #116.

Meadowbrook Advisors Group first reported a position in VRTX in Q4 2025 and has held it in 3 quarters since. The position peaked at $522K in Q4 2025. 1,744 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • Meadowbrook Advisors Group held 691 shares of Vertex Pharmaceuticals worth $343K as of Q2 2026.
  • Meadowbrook Advisors Group sold 427 Vertex Pharmaceuticals shares in Q2 2026, an estimated $189K.
  • Vertex Pharmaceuticals made up 0.18% of Meadowbrook Advisors Group's portfolio in Q2 2026, its #116 holding.
  • Meadowbrook Advisors Group first reported a position in Vertex Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
  • Meadowbrook Advisors Group's Vertex Pharmaceuticals position peaked at $522K in Q4 2025.
  • 1,744 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Meadowbrook Advisors Group's 13F filing for Q2 2026, filed 7 Aug 2026.